tetano
Editor, Senior Moderator
Can Commun Dis Rep
. 2023 Aug 1;49(7-8):351-357.
doi: 10.14745/ccdr.v49i78a07. Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program
Robyn Mitchell[SUP] 1 [/SUP], Diane Lee[SUP] 1 [/SUP], Linda Pelude[SUP] 1 [/SUP], Jeannette Comeau[SUP] 2 [/SUP], John Conly[SUP] 3 [/SUP], Chelsey Ellis[SUP] 4 [/SUP], Jennifer Ellison[SUP] 5 [/SUP], John Embil[SUP] 6 [/SUP], Gerald Evans[SUP] 7 [/SUP], Lynn Johnston[SUP] 8 [/SUP], Jennie Johnstone[SUP] 9 [/SUP], Kevin Katz[SUP] 10 [/SUP], Pamela Kibsey[SUP] 11 [/SUP], Bonita Lee[SUP] 12 [/SUP], Marie-Astrid Lefebvre[SUP] 13 [/SUP], Yves Longtin[SUP] 14 [/SUP], Allison McGeer[SUP] 9 [/SUP], Dominik Mertz[SUP] 15 [/SUP], Jessica Minion[SUP] 16 [/SUP], Stephanie Smith[SUP] 17 [/SUP], Jocelyn Srigley[SUP] 18 [/SUP], Kathryn Suh[SUP] 19 [/SUP], Jen Tomlinson[SUP] 6 [/SUP], Alice Wong[SUP] 20 [/SUP], Nisha Thampi[SUP] 21 [/SUP], Charles Frenette[SUP] 13 [/SUP]
Affiliations
Background: Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospitalized patients. This study describes the use and outcomes of nirmatrelvir-ritonavir among adults hospitalized with COVID-19 in a sentinel network of Canadian acute care hospitals during the Omicron variant phase of the pandemic.
Methods: The Canadian Nosocomial Infection Surveillance Program conducts surveillance of hospitalized patients with COVID-19 in acute care hospitals across Canada. Demographic, clinical, treatment and 30-day outcome data were collected by chart review by trained infection control professionals using standardized questionnaires.
Results: From January 1 to December 31, 2022, 13% (n=490/3,731) of adult patients (18 years of age and older) hospitalized with COVID-19 in 40 acute care hospitals received nirmatrelvir-ritonavir either at admission or during hospitalization. Most inpatients who received nirmatrelvir-ritonavir, 79% of whom were fully vaccinated, had at least one pre-existing comorbidity (97%) and were of advanced age (median=79 years). Few were admitted to an intensive care unit (2.3%) and among the 490 nirmatrelvir-ritonavir treated inpatients, there were 13 (2.7%) deaths attributable to COVID-19.
Conclusion: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines.
Keywords: COVID-19; Omicron; hospitalized patients; nirmatrelvir-ritonavir.
. 2023 Aug 1;49(7-8):351-357.
doi: 10.14745/ccdr.v49i78a07. Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program
Robyn Mitchell[SUP] 1 [/SUP], Diane Lee[SUP] 1 [/SUP], Linda Pelude[SUP] 1 [/SUP], Jeannette Comeau[SUP] 2 [/SUP], John Conly[SUP] 3 [/SUP], Chelsey Ellis[SUP] 4 [/SUP], Jennifer Ellison[SUP] 5 [/SUP], John Embil[SUP] 6 [/SUP], Gerald Evans[SUP] 7 [/SUP], Lynn Johnston[SUP] 8 [/SUP], Jennie Johnstone[SUP] 9 [/SUP], Kevin Katz[SUP] 10 [/SUP], Pamela Kibsey[SUP] 11 [/SUP], Bonita Lee[SUP] 12 [/SUP], Marie-Astrid Lefebvre[SUP] 13 [/SUP], Yves Longtin[SUP] 14 [/SUP], Allison McGeer[SUP] 9 [/SUP], Dominik Mertz[SUP] 15 [/SUP], Jessica Minion[SUP] 16 [/SUP], Stephanie Smith[SUP] 17 [/SUP], Jocelyn Srigley[SUP] 18 [/SUP], Kathryn Suh[SUP] 19 [/SUP], Jen Tomlinson[SUP] 6 [/SUP], Alice Wong[SUP] 20 [/SUP], Nisha Thampi[SUP] 21 [/SUP], Charles Frenette[SUP] 13 [/SUP]
Affiliations
- PMID: 38455882
- PMCID: PMC10917417
- DOI: 10.14745/ccdr.v49i78a07
Background: Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospitalized patients. This study describes the use and outcomes of nirmatrelvir-ritonavir among adults hospitalized with COVID-19 in a sentinel network of Canadian acute care hospitals during the Omicron variant phase of the pandemic.
Methods: The Canadian Nosocomial Infection Surveillance Program conducts surveillance of hospitalized patients with COVID-19 in acute care hospitals across Canada. Demographic, clinical, treatment and 30-day outcome data were collected by chart review by trained infection control professionals using standardized questionnaires.
Results: From January 1 to December 31, 2022, 13% (n=490/3,731) of adult patients (18 years of age and older) hospitalized with COVID-19 in 40 acute care hospitals received nirmatrelvir-ritonavir either at admission or during hospitalization. Most inpatients who received nirmatrelvir-ritonavir, 79% of whom were fully vaccinated, had at least one pre-existing comorbidity (97%) and were of advanced age (median=79 years). Few were admitted to an intensive care unit (2.3%) and among the 490 nirmatrelvir-ritonavir treated inpatients, there were 13 (2.7%) deaths attributable to COVID-19.
Conclusion: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines.
Keywords: COVID-19; Omicron; hospitalized patients; nirmatrelvir-ritonavir.